Peter Johann, Ph.D., is the Founder, Chairman & CEO of Lumendi Ltd, an innovative medical technology company that focuses on devices enabling endoluminal interventions. He also serves as Managing General Partner of NGN Capital since 2004. NGN is a healthcare venture capital firm managing the existing portfolio from prior Funds with offices in New York and Heidelberg, Germany.. Dr. Johann had successful IPOs and M&A transactions within his investment portfolio.
Prior to his current position, Dr. Johann held several positions in the healthcare industry, including Division Head of Corporate Development at Boehringer Ingelheim, where he was responsible for strategic planning and projects, M&A, business development and licensing. Prior to this, Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader Oncology Products. Other earlier positions include those at Boehringer Mannheim as Head of Business Development and Marketing Molecular Medicine; marketing, sales and business development responsibilities at Boehringer Mannheim Biochemicals including collaborations in the field of biopharmaceuticals.
Dr. Johann currently serves on the Board of Directors of Noxxon Pharma AG, Vivaldi Biosciences Inc. and Exosome Diagnostics Inc. He previously served on the Board of Directors of Micromet, Inc., Horizon Pharma Inc., Resverlogix Corp., Zenith Epigenetics Inc., Endosense SA, Jerini AG and NaniRx Therapeutics (now PIN Pharma).
Dr. Johann earned his Ph.D. from the Technical University Munich.